# PROSPER (NCT02003924)

> Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02003924
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Nonmetastatic Castration-Resistant Prostate Cancer; Prostate Cancer; Cancer of the Prostate
- Interventions: Enzalutamide; Placebo
- Enrollment: 1401
- Primary outcome: Metastasis Free Survival (MFS)

## Indexed commentary on PROSPER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prosper-nct02003924